All Big Pharma agree that the R&D crisis exists, but their approaches to dealing with it vary.
"R&D productivity is declining, don't let anyone tell you otherwise," declared Robert Ruffolo, PhD, president of R&D at Wyeth 's pharmaceuticals division, during this year's Pharmaceutical Strategic Alliances conference. All Big Pharma agree that the R&D crisis exists, but their approaches to dealing with it vary.
For Wyeth, it's a numbers game; Novartis AG is talking about an entirely new drug discovery grammar.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
